Skip to main content
. 2016 Oct 20;7(50):82554–82566. doi: 10.18632/oncotarget.12783

Figure 6. BBD-serum inhibited the LPS-induced HSCs proliferation by ERK signaling pathway.

Figure 6

(A) LPS-induced HSCs were treated with a gradient concentration of BBD-serum, and CCK-8 was performed to measure the proliferation at 24 h, 48 h, 72 h and 96 h. (B) The expression of Cyclin D1 in HSCs after administrated a different ratio BBD-serum by RT-PCR at 72 h. (C) Western blot was used to detect ERK and Cyclin D1 expressed in LPS-induced HSCs after treatment with BBD-serum at 72 h. Compared to10% N. with LPS group,*P < 0.05, **P < 0.01; by two-tailed Student's t test; N: normal-serum; B: BBD-serum.